异动解读｜强生盘中上涨3.02%，多项临床数据密集公布提振市场信心

行情直击06-06

6月6日，强生盘中上涨3.02%，报235.01美元/股，成交额9.15亿美元。

消息面上，强生近期密集披露多项关键临床数据。其中，Nipocalimab在系统性红斑狼疮二期研究中达到主要终点，24周时显著降低疾病活动度，并在自身抗体高活性干燥综合征患者中实现62.5%应答率。此外，Tecvayli治疗多发性骨髓瘤的晚期研究显示无进展生存期和总生存期均有统计学显著改善；Tremfya获FDA批签标签扩展；皮下注射amivantamab在头颈癌中实现42%客观缓解率。多条管线数据集中释放积极信号，为公司研发实力和未来增长预期提供支撑。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1141239715?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-06 02:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141239715","market":"hk","top_or_hot":-1,"title":"异动解读｜强生盘中上涨3.02%，多项临床数据密集公布提振市场信心","media":"行情直击","content":"<p><p>6月6日，强生盘中上涨3.02%，报235.01美元/股，成交额9.15亿美元。</p><p>消息面上，强生近期密集披露多项关键临床数据。其中，Nipocalimab在系统性红斑狼疮二期研究中达到主要终点，24周时显著降低疾病活动度，并在自身抗体高活性干燥综合征患者中实现62.5%应答率。此外，Tecvayli治疗多发性骨髓瘤的晚期研究显示无进展生存期和总生存期均有统计学显著改善；Tremfya获FDA批签标签扩展；皮下注射amivantamab在头颈癌中实现42%客观缓解率。多条管线数据集中释放积极信号，为公司研发实力和未来增长预期提供支撑。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜强生盘中上涨3.02%，多项临床数据密集公布提振市场信心</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜强生盘中上涨3.02%，多项临床数据密集公布提振市场信心\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-06 02:39 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>6月6日，强生盘中上涨3.02%，报235.01美元/股，成交额9.15亿美元。消息面上，强生近期密集披露多项关键临床数据。其中，Nipocalimab在系统性红斑狼疮二期研究中达到主要终点，24周时显著降低疾病活动度，并在自身抗体高活性干燥综合征患者中实现62.5%应答率。此外，Tecvayli治疗多发性骨髓瘤的晚期研究显示无进展生存期和总生存期均有统计学显著改善；Tremfya获FDA批签标签...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"JNJ","symbol_name":"强生","start_time":0,"source_url":"","article_id":"1141239715","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141239715","pubTimestamp":1780684749,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"6月6日，强生盘中上涨3.02%，报235.01美元/股，成交额9.15亿美元。消息面上，强生近期密集披露多项关键临床数据。其中，Nipocalimab在系统性红斑狼疮二期研究中达到主要终点，24周时显著降低疾病活动度，并在自身抗体高活性干燥综合征患者中实现62.5%应答率。多条管线数据集中释放积极信号，为公司研发实力和未来增长预期提供支撑。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"JNJ":"强生"},"translate_title":"Interpretation of the change | Johnson & Johnson rose 3.02% in the intraday session, and the intensive release of multiple clinical data boosted market confidence","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"JNJ":1},"content_text":"6月6日，强生盘中上涨3.02%，报235.01美元/股，成交额9.15亿美元。消息面上，强生近期密集披露多项关键临床数据。其中，Nipocalimab在系统性红斑狼疮二期研究中达到主要终点，24周时显著降低疾病活动度，并在自身抗体高活性干燥综合征患者中实现62.5%应答率。此外，Tecvayli治疗多发性骨髓瘤的晚期研究显示无进展生存期和总生存期均有统计学显著改善；Tremfya获FDA批签标签扩展；皮下注射amivantamab在头颈癌中实现42%客观缓解率。多条管线数据集中释放积极信号，为公司研发实力和未来增长预期提供支撑。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141239715","isCrawlerRequest":true}